IMTX / Immatics N.V. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Immatics Announces Second Quarter 2025 Financial Results and Business Update

Exhibit 99.2 PRESS RELEASE Immatics Announces Second Quarter 2025 Financial Results and Business Update • Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-tumor activity and durability in 33 heavily pretreated patients with metastatic melanoma in data from a Phase 1b trial presented at the 2025 ASCO Ann

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 13, 2025 Commission File Number: 001-39363 IMMATICS N.V.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 13, 2025 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of Principal Executive Office) Indicate by check mark whether the registr

PRELIMINARY NOTE

Exhibit 99.1 PRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three- and six-month period ended June 30, 2025, included herein, have been prepared in accordance with International Accounting Standard 34 (“Interim Financial Reporting”), as issued by the International Accounting Standards Board (“IASB”). The Consolidated Financial Statements are presented in

Forward-Looking Statement This presentation (“Presentation”) is provided by Immatics N.V. (“Immatics” or the “Company”) for informational purposes only. The information contained herein does not purport to be all-inclusive and none of Immatics, any o

Immatics Corporate Presentation August 13, 2025 Exhibit 99.3 Forward-Looking Statement This presentation (“Presentation”) is provided by Immatics N.V. (“Immatics” or the “Company”) for informational purposes only. The information contained herein does not purport to be all-inclusive and none of Immatics, any of its affiliates, any of its or their respective control persons, officers, directors, em

As filed with the Securities and Exchange Commission on July 1, 2025

As filed with the Securities and Exchange Commission on July 1, 2025 Registration No.

Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMATICS N.V. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered Securities

Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMATICS N.V. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered Securities Security Type Title of Securities to be Registered Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 18, 2025 Commission File Number: 001-39363 IMMATICS N.V

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 18, 2025 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the regist

MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF IMMATICS N.V. JUNE 18, 2025

Exhibit 99.1 MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF IMMATICS N.V. JUNE 18, 2025 Edward Sturchio, General Counsel of Immatics N.V. (the "Company"), opened the annual general meeting of the Company (the "Meeting") and designated Marloes van der Laan, candidate civil law notary of NautaDutilh N.V., the Company's Dutch legal counsel, as the secretary of the Meeting. The secretary of

IMMATICS N.V. 2025 STOCK OPTION AND INCENTIVE PLAN

Exhibit 99.4 IMMATICS N.V. 2025 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Immatics N.V. 2025 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of the Company and its Affiliates upon whose judgment, initiative and effort

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2, 2025 Commission File Number: 001-39363 IMMATICS N.V.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2, 2025 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the registr

Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation May 31, 2025

Exhibit 99.3 Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation May 31, 2025 Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive an

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2, 2025 Commission File Number: 001-39363 IMMATICS N.V.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2, 2025 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the registr

IMA203 PRAME Cell Therapy in Advanced Melanoma - Phase 1b Dose Expansion Clinical Data Update May 31, 2025 Data cut - off April 7, 2025 Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution.

Exhibit 99.2 IMA203 PRAME Cell Therapy in Advanced Melanoma - Phase 1b Dose Expansion Clinical Data Update May 31, 2025 Data cut - off April 7, 2025 Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Background and Key Takeaways • Frequent recurrence and limited long - term survival with unresectable or metastatic melanoma highlight the cri

EX-99.3

Exhibit 99.3

AGENDA OF THE ANNUAL GENERAL MEETING OF IMMATICS N.V.

Exhibit 99.2 AGENDA OF THE ANNUAL GENERAL MEETING OF IMMATICS N.V. Agenda of the annual general meeting of Immatics N.V., a public company under Dutch law, registered with the Dutch trade register under number 77595726 (the “Company”), to be held at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands on 18 June 2025 at 16:00 hours CEST (the “AGM”). 1. Opening 2

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

Exhibit 99.1 PRESS RELEASE Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma · Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with o

CONVENING NOTICE OF THE ANNUAL GENERAL MEETING OF IMMATICS N.V.

Exhibit 99.1 CONVENING NOTICE OF THE ANNUAL GENERAL MEETING OF IMMATICS N.V. This is the convening notice for the annual general meeting of Immatics N.V., a public company under Dutch law, registered with the Dutch trade register under number 77595726 (the “Company”), to be held at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands on 18 June 2025 at 16:00 hou

PRELIMINARY NOTE

Exhibit 99.1 PRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three-month period ended March 31, 2025, included herein, have been prepared in accordance with International Accounting Standard 34 (“Interim Financial Reporting”), as issued by the International Accounting Standards Board (“IASB”). The Consolidated Financial Statements are presented in euros.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 13, 2025 Commission File Number: 001-39363 IMMATICS N.V. Pa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 13, 2025 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of Principal Executive Office) Indicate by check mark whether the registrant

Immatics Announces First Quarter 2025 Financial Results and Business Update

Exhibit 99.2 PRESS RELEASE Immatics Announces First Quarter 2025 Financial Results and Business Update • IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026 • IMA203 PRAME Cell Therapy: Phase 1b clinical trial ongoing with updated data in metastatic melanoma with substantially longer fo

April 1, 2025

April 1, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with Immatics N.V.’s annual report on Form 20-F for the year ended December 31, 2024 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of

Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation March 27, 2025

Exhibit 99.2 Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation March 27, 2025 Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Harpreet Singh, certify that: 1. I have reviewed this annual report on Form 20-F of Immatics N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a mat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 27, 2025 Commission File Number: 001-39363 IMMATICS N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 27, 2025 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the regis

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON AND IMMATICS US, INC. AMENDMENT NUMBER 10 - FACILITIES/EQUIPMENT USE AND SERVICES AGREEMENT

Exhibit 4.21 THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON AND IMMATICS US, INC. AMENDMENT NUMBER 10 - FACILITIES/EQUIPMENT USE AND SERVICES AGREEMENT This Amendment Number 10 ("Amendment") to the Facilities/Equipment Use and Services Agreement ("Agreement") is entered into effective the 1st day of February 2025, by and between The University of Texas Health Science Center at Houston, (

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON AND IMMATICS US, INC. AMENDMENT NUMBER 9 - FACILITIES/EQUIPMENT USE AND SERVICES AGREEMENT

Exhibit 4.20 THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON AND IMMATICS US, INC. AMENDMENT NUMBER 9 - FACILITIES/EQUIPMENT USE AND SERVICES AGREEMENT This Amendment Number 9 ("Amendment") to the Facilities/Equipment Use and Services Agreement ("Agreement") is entered into effective the 1st day of May 2024, by and between The University of Texas Health Science Center at Houston, ("UTHeal

As filed with the Securities and Exchange Commission on March 27, 2025.

As filed with the Securities and Exchange Commission on March 27, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Immatics N.V. (Exact name of registrant as specified in its charter) The Netherlands Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

Calculation of Filing Fee Tables F-3 (Form Type) Immatics N.V. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables F-3 (Form Type) Immatics N.V. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with Immatics N.V.’s annual report on Form 20-F for the year ended December 31, 2024 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of

Immatics Announces Full Year 2024 Financial Results and Business Update

Exhibit 99.1 PRESS RELEASE Immatics Announces Full Year 2024 Financial Results and Business Update · Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as planned · ACTengine® IMA203 TCR-T (PRAME): Phase 1b IMA203 data published in October 2024 demonstrated a confirmed ORR of 54%

Policy version: 01

Exhibit 11.1 Policy P-GE-009-C-01 version: 01 IMMATICS N.V. INSIDER TRADING POLICY XX-Dec-2024 page of XX Author: Edward Sturchio Scope: Immatics N.V., Immatics Biotechnologies GmbH, Immatics US Inc. Approval: <> < > <> <> Table of Contents No table of contents entries found. 1. PURPOSE Immatics N.V. (together with its subsidiaries Immatics Biotechnologies GmbH and Immatics US Inc., “Immatics”, th

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-249408, 333-265820 and 333-280935) and on Form F-3 (Nos. 333-274218 and 333-24060) of IMMATICS N.V. of our report dated March 27, 2025, relating to the financial statements and the effectiveness of internal control over finan

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Arnd Christ, certify that: 1. I have reviewed this annual report on Form 20-F of Immatics N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a materi

IMTX / Immatics N.V. / Vestal Point Capital, LP - JOINT FILING AGREEMENT JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k)

EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The unders

CONTROL PERSON IDENTIFICATION

EX-99 3 d11603144ex99-b.htm Exhibit B CONTROL PERSON IDENTIFICATION Suvretta Capital Management, LLC is the relevant entity for which Aaron Cowen is the control person.

JOINT FILING AGREEMENT

EX-99 2 d11603144ex99-a.htm Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G dated February 11, 2025 relating to the ordinary shares, nominal value €0.01 per share, of Immatics N.V. shall be filed on behalf of the undersigned. SUVRETTA CAPITAL MANAGEMENT, LLC By: /s/ Aaron Cowen Name: Aaron Cowen Title: Authorized Signatory AVERILL MASTER FUND, LTD. By: /s/ Aaron Cowen

Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation January 13, 2025

Exhibit 99.1 Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation January 13, 2025 Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusiv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 13, 2025 Commission File Number: 001-39363 IMMATICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 13, 2025 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the reg

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 13, 2024 Commission File Number: 001-39363 IMMATICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 13, 2024 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the re

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell ther

Exhibit 99.2 PRESS RELEASE Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics • Today, Company discloses first clinical data from the TCR Bispecific molecule, TCER® IMA4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 18, 2024 Commission File Number: 001-39363 IMMATICS N.

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 18, 2024 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of Principal Executive Office) Indicate by check mark whether the r

PRELIMINARY NOTE

Exhibit 99.1 PRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three- and nine-month periods ended September 30, 2024, included herein, have been prepared in accordance with International Accounting Standard 34 (“Interim Financial Reporting”), as issued by the International Accounting Standards Board (“IASB”). The Consolidated Financial Statements are prese

IMA402 Phase 1 Dose Escalation Study Summary as of Nov 6, 2024 Data cut-off Nov 6, 2024 NT: not tested or not evaluable for PRAME expression; CRS: Cytokine release syndrome; DCR: Disease control rate For comprehensive patient flow chart, see appendix

TCR Bispecific Molecule TCER® IMA402 Targeting PRAME - Phase 1 Dose Escalation Clinical Data Update November 18, 2024 Data cut-off Nov 6, 2024 Exhibit 99.

Forward-Looking Statement This presentation (“Presentation”) is provided by Immatics N.V. (“Immatics” or the “Company”) for informational purposes only. The information contained herein does not purport to be all-inclusive and none of Immatics, any o

Immatics Corporate Presentation November 18, 2024 Exhibit 99.4 Forward-Looking Statement This presentation (“Presentation”) is provided by Immatics N.V. (“Immatics” or the “Company”) for informational purposes only. The information contained herein does not purport to be all-inclusive and none of Immatics, any of its affiliates, any of its or their respective control persons, officers, directors,

IMTX / Immatics N.V. / RTW INVESTMENTS, LP Passive Investment

SC 13G 1 p24-3256sc13g.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Immatics N.V. (Name of Issuer) Ordinary Shares, nominal value €0.01 per share (Title of Class of Securities) N44445109 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to desi

IMTX / Immatics N.V. / RTW INVESTMENTS, LP - JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K) JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned ackn

Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation November 8, 2024

Exhibit 99.2 Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation November 8, 2024 Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusiv

JOINT FILING AGREEMENT

EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Immatics N.V. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 8, 2024 Commission File Number: 001-39363 IMMATICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 8, 2024 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the reg

IMTX / Immatics N.V. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Immatics N.V. (Name of Issuer) Common Stock (Title of Class of Securities) N44445109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME Two oral presentations and multiple posters on clinical and preclinical-stage candidate

Exhibit 99.1 PRESS RELEASE Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics’ TCR-T PRAME franchise to target solid cancers · ACTengin

IMTX / Immatics N.V. / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment

SC 13D/A 1 d872355dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A* Under the Securities Exchange Act of 1934 (Amendment No. 1)* Immatics N.V. (Name of Issuer) Ordinary Shares, nominal value €0.01 per share (Title of Class of Securities) N44445109 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 15, 2024 Commission File Number: 001-39363 IMMATICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 15, 2024 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the reg

Immatics Announces Pricing of $150 Million Public Offering

Exhibit 99.2 PRESS RELEASE Immatics Announces Pricing of $150 Million Public Offering Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of its previously announced underwritten public offering

Immatics Announces Proposed $150 Million Public Offering

Exhibit 99.1 PRESS RELEASE Immatics Announces Proposed $150 Million Public Offering Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the commencement of an underwritten public offering of its ordinary sha

Immatics N.V. Ordinary Shares (Nominal value €0.01 per share) Underwriting Agreement

Exhibit 1.1 Immatics N.V. Ordinary Shares (Nominal value €0.01 per share) Underwriting Agreement October 10, 2024 Jefferies LLC Jefferies GmbH BofA Securities, Inc. Leerink Partners LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o Jefferies GmbH Bockenheimer Landstr. 24 60323 Frankfurt

IMMATICS N.V. 16,250,000 Ordinary Shares

Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-282569 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED OCTOBER 10, 2024) IMMATICS N.V. 16,250,000 Ordinary Shares We are offering 16,250,000 ordinary shares, nominal value €0.01 per share. The public offering price is $9.25 per ordinary share. Our ordinary shares are listed on The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol

Calculation of Filing Fee Tables (Form Type) Immatics N.V. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables F-3 (Form Type) Immatics N.V. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward

As filed with the Securities and Exchange Commission on October 10, 2024.

F-3ASR Table of Contents As filed with the Securities and Exchange Commission on October 10, 2024.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 10, 2024 Commission File Number: 001-39363 IMMATICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 10, 2024 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the reg

IMMATICS N.V. Ordinary Shares (Nominal value €0.01 per share) SALES AGREEMENT

Exhibit 1.2 IMMATICS N.V. Ordinary Shares (Nominal value €0.01 per share) SALES AGREEMENT October 10, 2024 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Immatics N.V., a public limited liability company (naamloze vennootschap) under Dutch law (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agen

Calculation of Filing Fee Tables (Form Type) Immatics N.V. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables F-3 (Form Type) Immatics N.V. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward 

IMMATICS N.V. $150,000,000 of Ordinary Shares

Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-282569 THE INFORMATION IN THIS PRELIMINARY PROSPECTUS SUPPLEMENT IS NOT COMPLETE AND MAY BE CHANGED. THIS PRELIMINARY PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS ARE NOT AN OFFER TO SELL THESE SECURITIES, AND WE ARE NOT SOLICITING OFFERS TO BUY THESE SECURITIES, IN ANY STATE OR OTHER JURISDICTION WHERE THE OFFER OR S

ACTengine® IMA203 TCR - T Targeting PRAME in PD1 Refractory Metastatic Melanoma - Phase 1b Dose Expansion Clinical Data Update October 10, 2024 Oral presentation by Martin Wermke at the Society of Melanoma Research Congress on October 11, 2024 Data c

Exhibit 99.2 ACTengine® IMA203 TCR - T Targeting PRAME in PD1 Refractory Metastatic Melanoma - Phase 1b Dose Expansion Clinical Data Update October 10, 2024 Oral presentation by Martin Wermke at the Society of Melanoma Research Congress on October 11, 2024 Data cut - off Aug 23, 2024 Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Forwar

Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation October 10, 2024

Exhibit 99.3 Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation October 10, 2024 Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusiv

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Exhibit 99.1 PRESS RELEASE Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST · Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 16, 2024 Commission File Number: 001-39363 IMMATIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 16, 2024 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the r

Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation September 16, 2024

Exhibit 99.3 Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation September 16, 2024 Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclus

TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 - Phase 1 Dose Escalation Clinical Data Update September 16, 2024 Oral presentation by Martin Wermke at the European Society of Medical Oncology Congress 2024 on September 16, 2024 Data cut - of

Exhibit 99.2 TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 - Phase 1 Dose Escalation Clinical Data Update September 16, 2024 Oral presentation by Martin Wermke at the European Society of Medical Oncology Congress 2024 on September 16, 2024 Data cut - off Jul 23, 2024 Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Forward - Loo

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

Exhibit 99.1 PRESS RELEASE Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update · TCER® IMA401 is a novel, next-generation, half-life extended bispecific T cell engager directed against an HLA-A*02-presented peptide derived from MAGEA4 and MAGEA8 with hig

Immatics Announces Second Quarter 2024 Financial Results and Business Update

Exhibit 99.2 PRESS RELEASE Immatics Announces Second Quarter 2024 Financial Results and Business Update • Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, median duration of response of 13.5 months; IMA203 continues to maintain a favorable tolerability profile • Registration-enabl

PRELIMINARY NOTE

Exhibit 99.1 PRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three- and six-month periods ended June 30, 2024, included herein, have been prepared in accordance with International Accounting Standard 34 (“Interim Financial Reporting”), as issued by the International Accounting Standards Board (“IASB”). The Consolidated Financial Statements are presented i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 13, 2024 Commission File Number: 001-39363 IMMATICS N.V.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 13, 2024 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of Principal Executive Office) Indicate by check mark whether the registr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 29, 2024 Commission File Number: 001-39363 IMMATICS N.V

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 29, 2024 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the regist

Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMATICS N.V. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered Securities

Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMATICS N.V. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered Securities Security Type Title of Securities to be Registered Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price

As filed with the Securities and Exchange Commission on July 22, 2024

As filed with the Securities and Exchange Commission on July 22, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 20, 2024 Commission File Number: 001-39363 IMMATICS N.V

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 20, 2024 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the regist

MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF IMMATICS N.V. JUNE 20, 2024

Exhibit 99.1 MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF IMMATICS N.V. JUNE 20, 2024 Edward Sturchio, General Counsel of Immatics N.V. (the "Company"), opened the annual general meeting of the Company (the "Meeting") and designated Marloes van der Laan, candidate civil law notary of NautaDutilh N.V., the Company's Dutch legal counsel, as the secretary of the Meeting. The secretary of

JOINT FILING AGREEMENT

EX-1 2 d839323dex1.htm EX-1 Exhibit 1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Dated:

IMTX / Immatics N.V. / ARYA SCIENCES HOLDINGS - SC 13G/A Passive Investment

SC 13G/A 1 d833662dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Immatics N.V. (Name of Issuer) Ordinary Shares, nominal value €0.01 per share (Title of Class of Securities) N44445109 (CUSIP Number) June 6, 2024 (Date of Event Which Requires Filing of this Statement) Check the

IMTX / Immatics N.V. / PERCEPTIVE ADVISORS LLC - SC 13D Activist Investment

SC 13D 1 d839323dsc13d.htm SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Immatics N.V. (Name of Issuer) Ordinary Shares, nominal value €0.01 per share (Title of Class of Securities) N44445109 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (N

EX-99.3

Exhibit 99.3

AGENDA of the ANNUAL GENERAL MEETING OF immatics N.V.

Exhibit 99.2 AGENDA of the ANNUAL GENERAL MEETING OF immatics N.V. Agenda of the annual general meeting of Immatics N.V., a public company under Dutch law, registered with the Dutch trade register under number 77595726 (the “Company”), to be held at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands on 20 June 2024 at 16:00 hours CEST (the “AGM”). 1. Opening 2

CONVENING NOTICE OF the ANNUAL GENERAL MEETING OF IMMATICS N.V.

Exhibit 99.1 CONVENING NOTICE OF the ANNUAL GENERAL MEETING OF IMMATICS N.V. This is the convening notice for the annual general meeting of Immatics N.V., a public company under Dutch law, registered with the Dutch trade register under number 77595726 (the “Company”), to be held at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands on 20 June 2024 at 16:00 hou

IMMATICS N.V. 2024 STOCK OPTION AND INCENTIVE PLAN

Exhibit 99.4 IMMATICS N.V. 2024 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Immatics N.V. 2024 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of the Company and its Affiliates upon whose judgment, initiative and effort

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 3, 2024 Commission File Number: 001-39363 IMMATICS N.V.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 3, 2024 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the registr

Forward-Looking Statement This presentation (“Presentation”) is provided by Immatics N.V. (“Immatics” or the “Company”) for informational purposes only. The information contained herein does not purport to be all-inclusive and none of Immatics, any o

Immatics Corporate Presentation May 14, 2024 Exhibit 99.3 Forward-Looking Statement This presentation (“Presentation”) is provided by Immatics N.V. (“Immatics” or the “Company”) for informational purposes only. The information contained herein does not purport to be all-inclusive and none of Immatics, any of its affiliates, any of its or their respective control persons, officers, directors, emplo

Immatics Announces First Quarter 2024 Financial Results and Business Update Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME

Exhibit 99.2 PRESS RELEASE Immatics Announces First Quarter 2024 Financial Results and Business Update Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME • Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, including tumo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 14, 2024 Commission File Number: 001-39363 IMMATICS N.V. Pa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 14, 2024 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of Principal Executive Office) Indicate by check mark whether the registrant

PRELIMINARY NOTE

Exhibit 99.1 PRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three-month period ended March 31, 2024, included herein, have been prepared in accordance with International Accounting Standard 34 (“Interim Financial Reporting”), as issued by the International Accounting Standards Board (“IASB”). The Consolidated Financial Statements are presented in euros.

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-249408 and 333-265820) and on Form F-3 (Nos. 333-274218, 333-258351 and 333-24060) of IMMATICS N.V. of our report dated March 21, 2024, relating to the financial statements and the effectiveness of internal control over finan

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

EX-12.1 Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Harpreet Singh, certify that: 1. I have reviewed this annual report on Form 20-F of Immatics N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to sta

LEASE AGREEMENT BETWEEN WEATHERFORD FARMS DC, L.P. AS LANDLORD, AND IMMATICS US, INC., AS TENANT DATED MARCH 24, 2022 STAFFORD, TEXAS Approved Texas Industrial Lease Form Based On Master Lease Version 22

Exhibit 4.21 LEASE AGREEMENT BETWEEN WEATHERFORD FARMS DC, L.P. AS LANDLORD, AND IMMATICS US, INC., AS TENANT DATED MARCH 24, 2022 STAFFORD, TEXAS Approved Texas Industrial Lease Form Based On Master Lease Version 22 BASIC LEASE INFORMATION Lease Date: March 24, 2022 Landlord: WEATHERFORD FARMS DC, L.P., a Delaware limited partnership Tenant: IMMATICS US, INC., a Delaware corporation Premises: Tha

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Exhibit 99.1 Immatics Announces Full Year 2023 Financial Results and Corporate Update · Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median follow-up of 14.4 months; IMA203 was well tolerated · Registration-enabling randomized Phase 2/3 trial for ACTengine®

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 21, 2024 Commission File Number: 001-39363 IMMATICS N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 21, 2024 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the regis

COMBINATION COLLABORATION PROJECT AGREEMENT pursuant to the COLLABORATION AND LICENSE AGREEMENT by and between IMMATICS US, INC. MODERNATX, INC. Dated as of September 7, 2023

Exhibit 4.20 EXHIBIT C COMBINATION COLLABORATION PROJECT AGREEMENT pursuant to the COLLABORATION AND LICENSE AGREEMENT by and between IMMATICS US, INC. and MODERNATX, INC. Dated as of September 7, 2023 Table of Contents Page ARTICLE 1 SCHEDULES, ORDER OF PRECEDENCE AND CONSTRUCTION 1 1.1 General 1 ARTICLE 2 DEFINITIONS 1 ARTICLE 3 GOVERNANCE 7 3.1 Combination Project Committee 7 ARTICLE 4 COLLABOR

© Immatics. Not for further reproduction or distribution. Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation March 21, 2024

Exhibit 99.2 © Immatics. Not for further reproduction or distribution. Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation March 21, 2024 Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The informatio

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

EX-13.2 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with Immatics N.V.’s annual report on Form 20-F for the year ended December 31, 2023 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

EX-13.1 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with Immatics N.V.’s annual report on Form 20-F for the year ended December 31, 2023 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange

MASTER COLLABORATION AND LICENSE AGREEMENT by and between IMMATICS BIOTECHNOLOGIES GMBH MODERNATX, INC. Dated as of September 7, 2023

Exhibit 4.17 MASTER COLLABORATION AND LICENSE AGREEMENT by and between IMMATICS BIOTECHNOLOGIES GMBH and MODERNATX, INC. Dated as of September 7, 2023 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 ARTICLE 2 RESEARCH 16 2.1 Collaboration Overview 16 2.2 Research Activities; Research Plan and Research Budget 16 2.3 Research Plan and Research Budget Updates 17 2.4 Briefing the JSC and Project Commit

IMMATICS N.V. COMPENSATION RECOUPMENT POLICY

Exhibit 97.1 IMMATICS N.V. COMPENSATION RECOUPMENT POLICY This Immatics N.V. Compensation Recoupment Policy (the “Policy”) has been adopted by the Board of Directors (the “Board”) of Immatics N.V. (the “Company”) on September 13, 2023. This Policy provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with finan

DATABASE / VACCINE COLLABORATION PROJECT AGREEMENT pursuant to the COLLABORATION AND LICENSE AGREEMENT by and between IMMATICS BIOTECHNOLOGIES GMBH MODERNATX, INC. Dated as of September 7, 2023

Exhibit 4.19 EXHIBIT B DATABASE / VACCINE COLLABORATION PROJECT AGREEMENT pursuant to the COLLABORATION AND LICENSE AGREEMENT by and between IMMATICS BIOTECHNOLOGIES GMBH and MODERNATX, INC. Dated as of September 7, 2023 TABLE OF CONTENTS Page ARTICLE 1 SCHEDULES, ORDER OF PRECEDENCE, AND CONSTRUCTION 1 1.1 General 1 ARTICLE 2 DEFINITIONS 2 ARTICLE 3 PROGRAM OVERVIEW 6 3.1 Collaboration Overview 6

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON IMMATICS US, INC.  AMENDMENT NUMBER 8 - FACILITIES/EQUIPMENT USE AND SERVICES AGREEMENT

Exhibit 4.22 THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON AND IMMATICS US, INC.  AMENDMENT NUMBER 8 - FACILITIES/EQUIPMENT USE AND SERVICES AGREEMENT This Amendment Number 8 (“Amendment”) to the Facilities/Equipment Use and Services Agreement (“Agreement”) is entered into effective the 1st day of May 2023, by and between The University of Texas Health Science Center at Houston, (“UTHea

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

EX-12.2 Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Arnd Christ, certify that: 1. I have reviewed this annual report on Form 20-F of Immatics N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state

MASTER SERVICES AGREEMENT

Exhibit 4.23 MASTER SERVICES AGREEMENT THIS MASTER SERVICES AGREEMENT (this “MSA”) is effective as of March 20, 2024 (“Effective Date”) between Patheon UK Limited, part of Thermo Fisher Scientific with offices located at Kingfisher Drive, Swindon, SN3 5BZ, United Kingdom (“Patheon”) and Immatics Biotechnologies GmbH, with offices located at Paul-Ehrlich-Str. 15, Tübingen, Baden-Wurttemberg, German

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SE

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

TCER COLLABORATION PROJECT AGREEMENT pursuant to the COLLABORATION AND LICENSE AGREEMENT by and between IMMATICS BIOTECHNOLOGIES GMBH MODERNATX, INC. Dated as of September 7, 2023

Exhibit 4.18 EXHIBIT A TCER COLLABORATION PROJECT AGREEMENT pursuant to the COLLABORATION AND LICENSE AGREEMENT by and between IMMATICS BIOTECHNOLOGIES GMBH and MODERNATX, INC. Dated as of September 7, 2023 TABLE OF CONTENTS Page ARTICLE 1 SCHEDULES, ORDER OF PRECEDENCE AND CONSTRUCTION 1 1.1 General 1 ARTICLE 2 DEFINITIONS 1 ARTICLE 3 RESEARCH; DILIGENCE 8 3.1 Collaboration Overview 8 3.2 Initial

IMTX / Immatics N.V. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment

SC 13G/A 1 tm242424d18sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 2)* Immatics N.V. (Name of Issuer) Ordinary Shares, nominal value £0.01 per share (Title of Class of Securities) N44445109 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriat

IMTX / Immatics N.V. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Immatics N.V. (Name of Issuer) Common Stock (Title of Class of Securities) N44445109 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig

IMTX / Immatics N.V. / ATHOS KG - SC 13G/A Passive Investment

SC 13G/A 1 d769663dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*  IMMATICS N.V. (Name of Issuer) Ordinary Shares, nominal value €1.00 per share (Title of Class of Securities) N44445109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check

IMTX / Immatics N.V. / ATHOS KG - SC 13G/A Passive Investment

SC 13G/A 1 d769017dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)*  IMMATICS N.V. (Name of Issuer) Ordinary Shares, nominal value €1.00 per share (Title of Class of Securities) N44445109 (CUSIP Number) January 22, 2024 (Date of Event Which Requires Filing of this Statement) Check t

Immatics N.V. Ordinary Shares (Nominal value €0.01 per share) Underwriting Agreement

Exhibit 1.1 Immatics N.V. Ordinary Shares (Nominal value €0.01 per share) Underwriting Agreement January 17, 2024 Jefferies LLC Jefferies GmbH BofA Securities, Inc. Leerink Partners LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o Jefferies GmbH Bockenheimer Landstr. 24 60323 Frankfurt

P R E S S R E L E A S E Immatics Announces Proposed Public Offering

Exhibit 99.1 P R E S S R E L E A S E Immatics Announces Proposed Public Offering Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the commencement of an underwritten public offering of its ordinary shares

© Immatics. Not for further reproduction or distribution. Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation January 22, 2024

Exhibit 99.3 © Immatics. Not for further reproduction or distribution. Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation January 22, 2024 Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The informat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 22, 2024 Commission File Number: 001-39363 IMMATICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 22, 2024 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the reg

P R E S S R E L E A S E Immatics Announces Pricing of $175 Million Public Offering

Exhibit 99.2 P R E S S R E L E A S E Immatics Announces Pricing of $175 Million Public Offering Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an underwritten public offering of 15,925,00

EX-FILING FEES

EX-FILING FEES Exhibit 107 The prospectus to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price for the securities registered by such prospectus is $201,451,250.

IMMATICS N.V. 15,925,000 Ordinary Shares

424B5 Table of Contents FILED PURSUANT TO RULE 424(B)(5) REGISTRATION NO. 333-258351 PROSPECTUS SUPPLEMENT (to Prospectus dated August 9, 2021) IMMATICS N.V. 15,925,000 Ordinary Shares We are offering 15,925,000 ordinary shares, nominal value €0.01 per share. The public offering price is $11.00 per ordinary share. Our ordinary shares are listed on The Nasdaq Stock Market LLC (“Nasdaq”) under the s

IMMATICS N.V. Ordinary Shares

424B5 Table of Contents FILED PURSUANT TO RULE 424(B)(5) REGISTRATION NO. 333-258351 THE INFORMATION IN THIS PRELIMINARY PROSPECTUS SUPPLEMENT IS NOT COMPLETE AND MAY BE CHANGED. THIS PRELIMINARY PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS ARE NOT AN OFFER TO SELL THESE SECURITIES, AND WE ARE NOT SOLICITING OFFERS TO BUY THESE SECURITIES, IN ANY STATE OR OTHER JURISDICTION WHERE THE OFFE

Immatics Announces Third Quarter 2023 Financial Results and Business Update

EX-99.2 Exhibit 99.2 PRESS RELEASE Immatics Announces Third Quarter 2023 Financial Results and Business Update • ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median duration of response (mDOR) not reached at median follow-up of 14.4 months including responses ongoing at >15 months after infusion; IMA203 GEN1 continues to be well tolerated;

PRELIMINARY NOTE

EX-99.1 Exhibit 99.1 PRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three and nine-month periods ended September 30, 2023, included herein, have been prepared in accordance with International Accounting Standard 34 (“Interim Financial Reporting”), as issued by the International Accounting Standards Board (“IASB”). The Consolidated Financial Statements ar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 14, 2023 Commission File Number: 001-39363 IMMATICS N.

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 14, 2023 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of Principal Executive Office) Indicate by check mark whether the r

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET IMA203 data with foc

Exhibit 99.1 PRESS RELEASE Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET IMA203 data with focus on melanoma patients presented at the International Congress of the Society for Melanoma Research today, November 8 · IM

© Immatics. Not for further reproduction or distribution. Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. ACTengine® IMA203 / IMA203CD8 TCR - T Monotherapy Targeting PRAME – Phase 1 Interim

Exhibit 99.2 © Immatics. Not for further reproduction or distribution. Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. ACTengine® IMA203 / IMA203CD8 TCR - T Monotherapy Targeting PRAME – Phase 1 Interim Data Update Martin Wermke , Professor at the University Hospital Dresden and Coordinating Investigator of the ACTengine ® IMA203 TCR - T

© Immatics. Not for further reproduction or distribution. Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation November 08, 2023

Exhibit 99.3 © Immatics. Not for further reproduction or distribution. Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation November 08, 2023 Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The informa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 8, 2023 Commission File Number: 001-39363 IMMATICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 8, 2023 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the reg

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 24, 2023 Commission File Number: 001-39363 IMMATICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 24, 2023 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the reg

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

Exhibit 99.1 PRESS RELEASE Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy · RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer types · Regulatory activities underway with an initial focus on a registration-dir

IMMATICS N.V. 2,419,818 Ordinary Shares

Filed Pursuant to Rule 424(b)(3) Registration No. 333-274218 PROSPECTUS IMMATICS N.V. 2,419,818 Ordinary Shares This prospectus relates to the offer and sale from time to time by Bristol-Myers Squibb Company (the “selling securityholder”) of up to 2,419,818 of our ordinary shares, €0.01 nominal value per share. This prospectus also covers any additional securities that may become issuable by reaso

September 11, 2023

September 11, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 11, 2023 Commission File Number: 001-39363 IMMATIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 11, 2023 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the r

© Immatics. Not for further reproduction or distribution. Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation September 11, 2023

Exhibit 99.2 © Immatics. Not for further reproduction or distribution. Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation September 11, 2023 Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The inform

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

Exhibit 99.1 PRESS RELEASE Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics · Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules · Companies to leverage Immatics’ XPRESIDENT® target discovery platform and Moderna’s mRNA technology for the development of novel cancer vacc

SECURITIES PURCHASE AGREEMENT

Exhibit 4.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of July 19, 2023 by and between Immatics N.V., a public limited liability company (naamloze vennootschap) under Dutch law (the “Company”), and Bristol-Myers Squibb Company (the “Investor”). Recitals A. The Company and the Investor are executing and delivering this Agreement i

Calculation of Filing Fee Table (Form Type) Immatics N.V. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Table F-3 (Form Type) Immatics N.V. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registratio

As filed with the Securities and Exchange Commission on August 25, 2023.

As filed with the Securities and Exchange Commission on August 25, 2023. Registration No. 333-       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Immatics N.V. (Exact name of registrant as specified in its charter) The Netherlands Not Applicable (State or other jurisdiction of incorporation or organization)

PRELIMINARY NOTE

Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and six-month periods ended June 30, 2023, included herein, have been prepared in accordance with International Accounting Standard 34 (“Interim Financial Reporting”), as issued by the International Accounting Standards Board (“IASB”). The Consolidated Financial Statements are presented in euros.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 17, 2023 Commission File Number: 001-39363 IMMATICS N.V.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 17, 2023 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of Principal Executive Office) Indicate by check mark whether the registr

Immatics Announces Second Quarter 2023 Financial Results and Business Update

Exhibit 99.2 PRESS RELEASE Immatics Announces Second Quarter 2023 Financial Results and Business Update • Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting PRAME • ACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on 11 heavily pre-treated patients i

Forward-Looking Statement This presentation (“Presentation”) is provided by Immatics N.V. (“Immatics” or the “Company”) for informational purposes only. The information contained herein does not purport to be all-inclusive and none of Immatics, any o

Immatics Corporate Presentation August 17, 2023 Exhibit 99.3 Forward-Looking Statement This presentation (“Presentation”) is provided by Immatics N.V. (“Immatics” or the “Company”) for informational purposes only. The information contained herein does not purport to be all-inclusive and none of Immatics, any of its affiliates, any of its or their respective control persons, officers, directors, em

IMTX / Immatics N.V / ATHOS KG - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IMMATICS N.V. (Name of Issuer) Ordinary Shares, nominal value €1.00 per share (Title of Class of Securities) N44445109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t

JOINT FILING AGREEMENT

EX-99.1 2 d499927dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersign

Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

Exhibit 99.1 PRESS RELEASE Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors · TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic · Patient enrollment for IMA402 Phase 1/2 trial underway · The trial will evaluate safety, tolerability, and anti-tumor activity of IMA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 10, 2023 Commission File Number: 001-39363 IMMATICS N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 10, 2023 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the regi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 24, 2023 Commission File Number: 001-39363 IMMATICS N.V

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 24, 2023 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the regist

Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb

PRESS RELEASE Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb Tuebingen, Germany and Houston, TX July 24, 2023 – Immatics N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 20, 2023 Commission File Number: 001-39363 IMMATICS N.V

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 20, 2023 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the regist

MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF IMMATICS N.V. JUNE 20, 2023

Exhibit 99.1 MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF IMMATICS N.V. JUNE 20, 2023 Edward Sturchio, General Counsel of Immatics N.V. (the "Company"), opened the annual general meeting of the Company (the "Meeting") and designated Paul van der Bijl, civil law notary of NautaDutilh N.V., the Company's Dutch legal counsel, as the secretary of the Meeting. The secretary of the Meeting n

EX-99.3

Exhibit 99.3

CONVENING NOTICE OF the ANNUAL GENERAL MEETING OF IMMATICS N.V.

Exhibit 99.1 CONVENING NOTICE OF the ANNUAL GENERAL MEETING OF IMMATICS N.V. This is the convening notice for the annual general meeting of Immatics N.V., a public company under Dutch law, registered with the Dutch trade register under number 77595726 (the “Company”), to be held at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands on 20 June 2023 at 14:00 hou

AGENDA of the ANNUAL GENERAL MEETING OF immatics N.V.

Exhibit 99.2 AGENDA of the ANNUAL GENERAL MEETING OF immatics N.V. Agenda of the annual general meeting of Immatics N.V., a public company under Dutch law, registered with the Dutch trade register under number 77595726 (the “Company”), to be held at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands on 20 June 2023 at 14:00 hours CEST (the “AGM”). 1. Opening 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 23, 2023 Commission File Number: 001-39363 IMMATICS N.V.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 23, 2023 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the registr

PRELIMINARY NOTE

EX-99.1 Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three-month period ended March 31, 2023, included herein, have been prepared in accordance with International Accounting Standard 34 (“Interim Financial Reporting”), as issued by the International Accounting Standards Board (“IASB”). The Consolidated Financial Statements are presented in euros.

Immatics Announces First Quarter 2023 Financial Results and Business Update

EX-99.2 Exhibit 99.2 PRESS RELEASE Immatics Announces First Quarter 2023 Financial Results and Business Update • ACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on heavily pretreated 11 patients in Phase 1b dose expansion Cohort A with median duration of response not reached at a median follow-up time of 8.5 months at data cut-off • Objectiv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 16, 2023 Commission File Number: 001-39363 IMMATICS N.V. Pa

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 16, 2023 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of Principal Executive Office) Indicate by check mark whether the regist

Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME Company to host conference call today, May 2, at 8:30 am EDT / 2:30 pm CEST

Exhibit 99.1 PRESS RELEASE Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME Company to host conference call today, May 2, at 8:30 am EDT / 2:30 pm CEST · Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203 TCR-T monotherapy against PRAME · Objective r

Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation May 2, 2023

Exhibit 99.3 Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation May 2, 2023 Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2, 2023 Commission File Number: 001-39363 IMMATICS N.V.

6-K 1 dp1931606k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 2, 2023 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by c

Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. ACTengine® IMA203 TCR - T Monotherapy Targeting PRAME – Phase 1b Cohort A Interim Data Update Martin Wermke , Professor at the University Hos

Exhibit 99.2 Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. ACTengine® IMA203 TCR - T Monotherapy Targeting PRAME – Phase 1b Cohort A Interim Data Update Martin Wermke , Professor at the University Hospital Dresden and Coordinating Investigator of the ACTengine® IMA203 TCR - T trial Cedrik Britten , Chief Medical Officer, Immatics Harpr

Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration

Exhibit 99.1 PRESS RELEASE Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration · Bristol Myers Squibb exercised its first option and entered into a global license agreement with Immatics for the most advanced TCR-T product candidate from the companies’ ongoing collaboration to develop four TCR-based adoptive cell therapies targe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 1, 2023 Commission File Number: 001-39363 IMMATICS N.V.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 1, 2023 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the registra

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

EX-12.1 Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Harpreet Singh, certify that: 1. I have reviewed this annual report on Form 20-F of Immatics N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to sta

Collaboration Agreement, dated as of June 1, 2022, by and between Immatics US, Inc. and Celgene Switzerland LLC

EX-4.17 Exhibit 4.17 Certain confidential information contained in this document, marked by [**], has been omitted because Immatics N.V. (the “Company”) has determined that the information (i) is not material and (ii) is customarily and actually treated by the Company as private or confidential. COLLABORATION AGREEMENT by and between IMMATICS US, INC. and CELGENE SWITZERLAND LLC Dated as of June 1

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

EX-12.2 Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Arnd Christ, certify that: 1. I have reviewed this annual report on Form 20-F of Immatics N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

EX-13.1 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with Immatics N.V.’s annual report on Form 20-F for the year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange

Consent of PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft

Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-249408 and 333-265820) and on Form F-3 (Nos. 333-258351 and 333-24060) of IMMATICS N.V. of our report dated March 22, 2023 relating to the financial statements, which appears in this Form 20-F. Stuttgart, Germany March 22, 20

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

EX-13.2 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with Immatics N.V.’s annual report on Form 20-F for the year ended December 31, 2022 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange

Immatics Announces Full Year 2022 Financial Results and Corporate Update

Exhibit 99.1 Immatics Announces Full Year 2022 Financial Results and Corporate Update · ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target dose in different solid cancers in an interim clinical update in Phase 1a and Phase 1b in October 2022 · ACTengine® IMA203 TCR-T clinical data update on all three ongoing IMA203 Phase 1b coho

© Immatics. Not for further reproduction or distribution. Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation March 22, 2023

Exhibit 99.2 © Immatics. Not for further reproduction or distribution. Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation March 22, 2023 Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The informatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 22, 2023 Commission File Number: 001-39363 IMMATICS N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 22, 2023 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the regis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 13, 2023 Commission File Number: 001-39363 IMMATICS N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 13, 2023 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the regis

IMTX / Immatics NV / Nantahala Capital Management, LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm236168d25sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IMMATICS N.V. (Name of Issuer) Ordinary shares, nominal value €0.01 per share (Title of Class of Securities) N44445109 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Chec

IMTX / Immatics NV / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment

SC 13G/A 1 tm234999d13sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Immatics N.V. (Name of Issuer) Ordinary Shares, nominal value £0.01 per share (Title of Class of Securities) N44445109 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriat

IMTX / Immatics NV / dievini Hopp BioTech holding GmbH & Co KG - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 ea173206-13ga2dieviniimmat.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Under the Securities Exchange Act of 1934 (Amendment No. 2) IMMATICS N.V. (Name of Issuer) Ordinary shares, nominal value €0.01 per share (Title of Class of Securities) N44445109 (CUSIP Number) December 31, 2022 (Date of Event

IMTX / Immatics NV / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Immatics N.V. (Name of Issuer) Common Stock (Title of Class of Securities) N44445109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i

© Immatics. Not for further reproduction or distribution. Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation January 09, 2023

Exhibit 99.1 © Immatics. Not for further reproduction or distribution. Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation January 09, 2023 Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The informat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 9, 2023 Commission File Number: 001-39363 IMMATICS N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 9, 2023 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the regi

PRELIMINARY NOTE

Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and nine-month periods ended September 30, 2022, included herein, have been prepared in accordance with International Accounting Standard 34 (?Interim Financial Reporting?), as issued by the International Accounting Standards Board (?IASB?). The Consolidated Financial Statements are presented in e

Immatics Announces Third Quarter 2022 Financial Results and Business Update

Exhibit 99.2 Immatics Announces Third Quarter 2022 Financial Results and Business Update ? Interim clinical update on ACTengine? IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective response rate (cORR) of 50% (6/12) at or above target dose across Phase 1a and Phase 1b; confirmed responses seen across different solid tumor types: cutaneous melanoma, ovarian cancer, head a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 17, 2022 Commission File Number: 001-39363 IMMATICS N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 17, 2022 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Stra?e 15 72076 T?bingen, Federal Republic of Germany (Address of Principal Executive Office) Indicate by check mark whether the regis

EXPLANATORY NOTE

Exhibit 99.4 EXPLANATORY NOTE This ?Material Dutch Tax Considerations? section is being provided to update disclosure in Immatics N.V.?s Annual Report on Form 20-F for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission as a result of subsequent changes in Dutch tax law. This section shall be deemed to be incorporated by reference into (i) the registration state

Immatics Corporate Presentation November 17, 2022 Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution.

Exhibit 99.3 Immatics Corporate Presentation November 17, 2022 Delivering the Power of T cells to Cancer Patients ? Immatics. Not for further reproduction or distribution. Forward-Looking Statement This presentation (?Presentation?) is provided by Immatics N.V. (?Immatics? or the ?Company?) for informational purposes only. The information contained herein does not purport to be all- inclusive and

Next-Generation TCR Bispecifics (TCER) Targeting Peptide-HLA Antigens for the Treatment of Patients with Solid Tumors

Exhibit 99.1 Next-Generation TCR Bispecifics (TCER) Targeting Peptide-HLA Antigens for the Treatment of Patients with Solid Tumors S. Bunk1, M. Hofmann1, G. Pszolla1, F. Schwoebel1, M. Hutt1, F. Unverdorben1, N. Aschmoneit1, M. Mølhøj1, C. Wagner1, M. Jaworski1, C. Schraeder1, H. Schuster1, S. Missel1, T. Weinschenk2, D. Maurer1, C. Reinhardt2 1 Immatics Biotechnologies GmbH, Tuebingen, Germany, 2

The PRAME Opportunity – High Peptide Copy Numbers, Homogenous Expression and High Prevalence to Address a Broad Patient Population across Different Solid Cancers with TCR-based Therapeutics

Exhibit 99.2 The PRAME Opportunity – High Peptide Copy Numbers, Homogenous Expression and High Prevalence to Address a Broad Patient Population across Different Solid Cancers with TCR-based Therapeutics J. Hukelmann1, C. M. Britten2, D. Araujo3, L. Backert1, C. Bokemeyer4, R. Caravajal5, M. Chatterjee6, A. Dash7, L. Freudenmann1, J. Fritsche1, D. Fuhrmann1, V. Goldfinger1, T. Holderried8, F. Hoffg

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 10, 2022 Commission File Number: 001-39363 IMMATICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 10, 2022 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the re

Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation October 18, 2022

Exhibit 99.1 Delivering the Power of T cells to Cancer Patients ? Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation October 18, 2022 Forward - Looking Statement This presentation (?Presentation?) is provided by Immatics N . V . (?Immatics? or the ?Company?) for informational purposes only . The information contained herein does not purport to be all - inclusiv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 18, 2022 Commission File Number: 001-39363 IMMATICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 18, 2022 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Stra?e 15 72076 T?bingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the reg

Immatics N.V. Ordinary Shares (Nominal value €0.01 per share) Underwriting Agreement

Exhibit 1.1 Immatics N.V. Ordinary Shares (Nominal value ?0.01 per share) Underwriting Agreement October 10, 2022 Jefferies LLC Jefferies GmbH SVB Securities LLC As representatives (the ?Representatives?) of the several Underwriters named in Schedule I hereto, c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o Jefferies GmbH Bockenheimer Landstr. 24 60323 Frankfurt am Main c/o SVB Securit

Immatics Announces $110 Million Underwritten Offering of Ordinary Shares

Exhibit 99.1 PRESS RELEASE Immatics Announces $110 Million Underwritten Offering of Ordinary Shares Houston, Texas and Tuebingen, Germany, October 10, 2022 ? Immatics N.V. (NASDAQ: IMTX, ?Immatics?), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today that it has agreed to sell, by way of an underwritten p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 12, 2022 Commission File Number: 001-39363 IMMATICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 12, 2022 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the reg

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 11, 2022 Commission File Number: 001-39363 IMMATICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 11, 2022 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Stra?e 15 72076 T?bingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the reg

IMMATICS N.V. 10,905,000 Ordinary Shares

TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5) ?Registration No. 333-258351 ? PROSPECTUS SUPPLEMENT (to PROSPECTUS DATED AUGUST 9, 2021) IMMATICS N.V.? 10,905,000 Ordinary Shares? We are offering 10,905,000 ordinary shares, nominal value ?0.01 per share. The public offering price is $10.09 per ordinary share. Our ordinary shares are listed on The Nasdaq Stock Market LLC (?Nasdaq?) under the s

IMMATICS N.V. Ordinary Shares

TABLE OF CONTENTS The information in this prospectus is not complete and may be changed.

Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME Company to host conference call today, October 10, at 8:30 am EDT / 2:30 pm CEST

Exhibit 99.1 PRESS RELEASE Immatics Reports Interim Clinical Data Update on ACTengine? IMA203 TCR-T Monotherapy Targeting PRAME Company to host conference call today, October 10, at 8:30 am EDT / 2:30 pm CEST ? Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in different solid cancers, in patients with high and low PRAME expressi

Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. ACTengine® IMA203 TCR - T Targeting PRAME Cedrik Britten, Chief Medical Officer Harpreet Singh, Chief Executive Officer October 10, 2022 – Mo

Exhibit 99.2 Delivering the Power of T cells to Cancer Patients ? Immatics. Not for further reproduction or distribution. ACTengine? IMA203 TCR - T Targeting PRAME Cedrik Britten, Chief Medical Officer Harpreet Singh, Chief Executive Officer October 10, 2022 ? Monotherapy Interim Data Update Forward - Looking Statement This presentation (?Presentation?) is provided by Immatics N . V . (?Immatics?

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 12, 2022 Commission File Number: 001-39363 IMMATIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 12, 2022 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Stra?e 15 72076 T?bingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the r

Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

Exhibit 99.1 PRESS RELEASE Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 ? TCER? IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presented peptide derived from PRAME ? In preclinical studies, IMA402 demonstrated enhanced anti-tumor activit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 23, 2022 Commission File Number: 001-39363 IMMATICS N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 23, 2022 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Stra?e 15 72076 T?bingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the regi

Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME

Exhibit 99.1 PRESS RELEASE Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine? TCR-T Candidate IMA203CD8 Targeting PRAME ? IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics? proprietary CD8?? co-receptor engaging functional CD4 and CD8 T cells directed against PRAME ? Preclinical data with IMA203CD8 showed enhanced potency and prolonged anti-tumor

Immatics Announces Second Quarter 2022 Financial Results and Business Update

Exhibit 99.2 PRESS RELEASE Immatics Announces Second Quarter 2022 Financial Results and Business Update ? ACTengine? TCR-T cell therapy targeting PRAME is enrolling patients in all three Phase 1b cohorts: IMA203 monotherapy at provisional recommended Phase 2 dose (RP2D) (Cohort A), IMA203/nivolumab checkpoint inhibitor combination (Cohort B) and IMA203CD8 2nd generation monotherapy (Cohort C) ? TC

PRELIMINARY NOTE

Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and six-month periods ended June 30, 2022, included herein, have been prepared in accordance with International Accounting Standard 34 (?Interim Financial Reporting?), as issued by the International Accounting Standards Board (?IASB?). The Consolidated Financial Statements are presented in euros.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 9, 2022 Commission File Number: 001-39363 IMMATICS N.V.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 9, 2022 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Stra?e 15 72076 T?bingen, Federal Republic of Germany (Address of Principal Executive Office) Indicate by check mark whether the registra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 30, 2022 Commission File Number: 001-39363 IMMATICS N.V

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 30, 2022 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Stra?e 15 72076 T?bingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the regist

© Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation June 30, 2022

Exhibit 99.1 ? Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation June 30, 2022 Forward - Looking Statements 2 This presentation (?Presentation?) is provided by Immatics N . V . (?Immatics? or the ?Company?) for informational purposes only . The information contained herein does not purport to be all - inclusive and Immatics nor any of its affiliates nor any of

Calculation of Filing Fee Tables Form S-8 (Form Type) IMMATICS N.V. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities

EX-FILING FEES 4 dp175845ex10701.htm EXHIBIT 107.1 Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) IMMATICS N.V. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(

As filed with the Securities and Exchange Commission on June 24, 2022

As filed with the Securities and Exchange Commission on June 24, 2022 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 14, 2022 Commission File Number: 001-39363 IMMATICS N.V

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 14, 2022 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Stra?e 15 72076 T?bingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the regist

MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF IMMATICS N.V. JUNE 13, 2022

Exhibit 99.1 MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF IMMATICS N.V. JUNE 13, 2022 Edward Sturchio, General Counsel of Immatics N.V. (the "Company"), opened the annual general meeting of the Company (the "Meeting") and designated Paul van der Bijl, civil law notary of NautaDutilh N.V., the Company's Dutch legal counsel, as the secretary of the Meeting. The secretary of the Meeting n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 13, 2022 Commission File Number: 001-39363 IMMATICS N.V

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 13, 2022 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Stra?e 15 72076 T?bingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the regist

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 7, 2022 Commission File Number: 001-39363 IMMATICS N.V.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 7, 2022 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Stra?e 15 72076 T?bingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the registr

Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer

PRESS RELEASE Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer Tuebingen, Germany; Houston, Texas; and Cambridge, Mass.

Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs

Exhibit 99.1 PRESS RELEASE Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs ? New multi-program collaboration to develop allogeneic TCR-T/CAR-T programs brings together Immatics? allogeneic gamma delta T cell therapy platform ACTallo? with Bristol Myers Squibb?s technologies and oncology drug development expertise ? Immatics to rec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 June 2, 2022 Commission File Number: 001-39363 IMMATICS N.V. Pa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 June 2, 2022 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Stra?e 15 72076 T?bingen, Federal Republic of Germany (Address of Principal Executive Office) Indicate by check mark whether the registrant

Immatics Announces First Quarter 2022 Financial Results and Business Update

Exhibit 99.2 PRESS RELEASE Immatics Announces First Quarter 2022 Financial Results and Business Update ? ACTengine? IMA203: First patients treated at RP2D in Phase 1b cohort A with IMA203 monotherapy as well as Phase 1b cohort B with IMA203/checkpoint inhibitor combination. IND for Phase 1b cohort C with 2nd-generation IMA203CD8 granted ? Phase 1 clinical trial initiated with the first T cell enga

PRELIMINARY NOTE

Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three-month period ended March 31, 2022, included herein, have been prepared in accordance with International Accounting Standard 34 (?Interim Financial Reporting?), as issued by the International Accounting Standards Board (?IASB?). The Consolidated Financial Statements are presented in euros. All refe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2, 2022 Commission File Number: 001-39363 IMMATICS N.V.

6-K 1 dp1745496k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 2, 2022 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Straße 15 72076 Tübingen, Federal Republic of Germany (Address of principal executive office) Indicate by

Forward-Looking Statements This presentation (“Presentation”) is provided by Immatics N.V. (“Immatics” or the “Company”) for informational purposes only. The information contained herein does not purport to be all-inclusive and Immatics nor any of it

EX-99.3 Immatics Corporate Presentation June 02, 2022 Exhibit 99.3 Forward-Looking Statements This presentation (“Presentation”) is provided by Immatics N.V. (“Immatics” or the “Company”) for informational purposes only. The information contained herein does not purport to be all-inclusive and Immatics nor any of its affiliates nor any of its or their control persons, officers, directors, employee

IMMATICS N.V. 2022 STOCK OPTION AND INCENTIVE PLAN

Exhibit 99.4 IMMATICS N.V. 2022 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Immatics N.V. 2022 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of the Company and its Affiliates upon whose judgment, initiative and effort

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 27, 2022 Commission File Number: 001-39363 IMMATICS N.V.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 27, 2022 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Stra?e 15 72076 T?bingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the registr

AGENDA of the ANNUAL GENERAL MEETING OF immatics N.V.

Exhibit 99.2 AGENDA of the ANNUAL GENERAL MEETING OF immatics N.V. Agenda of the annual general meeting of Immatics N.V., a public company under Dutch law, registered with the Dutch trade register under number 77595726 (the "Company"), to be held at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands on 13 June 2022 at 14:00 hours CEST (the "AGM"). 1. Opening 2

Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DAT

EXHIBIT 99.3 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. D72926 - P71822 For Against Abstain For Against Abstain ! ! ! ! ! ! ! ! ! Please sign exactly as your name(s) appear(s) hereon . When

CONVENING NOTICE OF the ANNUAL GENERAL MEETING OF IMMATICS N.V.

Exhibit 99.1 CONVENING NOTICE OF the ANNUAL GENERAL MEETING OF IMMATICS N.V. This is the convening notice for the annual general meeting of Immatics N.V., a public company under Dutch law, registered with the Dutch trade register under number 77595726 (the "Company"), to be held at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands on 13 June 2022 at 14:00 hou

Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors

Exhibit 99.1 PRESS RELEASE Immatics Announces First Patient Treated with ACTengine? IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo? (nivolumab) in Patients with Advanced Solid Tumors ? The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab1, a PD-1 immune checkpoint inh

© Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation May 18, 2022

Exhibit 99.2 ? Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation May 18, 2022 Forward - Looking Statements 2 This presentation (?Presentation?) is provided by Immatics N . V . (?Immatics? or the ?Company?) for informational purposes only . The information contained herein does not purport to be all - inclusive and Immatics nor any of its affiliates nor any of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 18, 2022 Commission File Number: 001-39363 IMMATICS N.V.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 18, 2022 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Stra?e 15 72076 T?bingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the registr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 10, 2022 Commission File Number: 001-39363 IMMATICS N.V.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 10, 2022 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Stra?e 15 72076 T?bingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the registr

© Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation May 10, 2022

Exhibit 99.2 ? Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation May 10, 2022 Forward - Looking Statements 2 This presentation (?Presentation?) is provided by Immatics N . V . (?Immatics? or the ?Company?) for informational purposes only . The information contained herein does not purport to be all - inclusive and Immatics nor any of its affiliates nor any of

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

Exhibit 99.1 PRESS RELEASE Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors ? Patient enrollment for IMA401 Phase 1 trial started at first clinical site in Germany ? The study will evaluate safety, tolerability, and initial anti-tumor activity of IMA401 in patients with recurrent and/or refractory solid tumors ? TCER? IMA401 ta

License, Development and Commercialization Agreement, dated as of December 10, 2021, by and between Immatics Biotechnologies GmbH and Bristol-Myers Squibb Company

Exhibit 4.16 Certain confidential information contained in this document, marked by [**], has been omitted because Immatics N.V. has determined that the information (i) is not material and (ii) is the type that Immatics N.V. customarily and actually treats as private or confidential. LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT DATED AS OF DECEMBER 10, 2021 BY AND BETWEEN IMMATICS BIOTECHN

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

EX-13.1 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with Immatics N.V.’s annual report on Form 20-F for the year ended December 31, 2021 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

EX-12.1 Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Harpreet Singh, certify that: 1. I have reviewed this annual report on Form 20-F of Immatics N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to sta

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

EX-12.2 Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Arnd Christ, certify that: 1. I have reviewed this annual report on Form 20-F of Immatics N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state

© Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation March 23, 2022 1

Exhibit 99.2 ? Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation March 23, 2022 1 Forward - Looking Statements 2 This presentation (?Presentation?) is provided by Immatics N . V . (?Immatics? or the ?Company?) for informational purposes only . The information contained herein does not purport to be all - inclusive and Immatics nor any of its affiliates nor any

Immatics Announces Full Year 2021 Financial Results and Corporate Update

Exhibit 99.1 PRESS RELEASE Immatics Announces Full Year 2021 Financial Results and Corporate Update ? IMA203 TCR-T candidate targeting PRAME demonstrated a 50% objective response rate across different solid tumor types in an interim update of Phase 1a dose escalation ? Multiple IMA203 Phase 1b expansion cohorts being initiated in Q2 2022 including monotherapy at target dose level, checkpoint combi

Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Share Capital Authorized Share Capital Our authorized share capital consists of 285,000,000 ordinary shares, nominal value of ?0.01 per share, and 15,000,000 financing preferred shares. The financing preferred shares are divided into five series, each consisting of 3,000,000 financing pre

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with Immatics N.V.?s annual report on Form 20-F for the year ended December 31, 2021 (the ?Report?) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of

Consent of PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft

Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-249408), Registration Statement on Form F-3 (No. 333-258351) and Registration Statement on Post-Effective Amendment No. 2 to Form F-1 on Form F-3 (No. 333-240260) of Immatics N.V. of our report dated March 23, 2022 relating to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SE

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 23, 2022 Commission File Number: 001-39363 IMMATICS N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 23, 2022 Commission File Number: 001-39363 IMMATICS N.V. Paul-Ehrlich-Stra?e 15 72076 T?bingen, Federal Republic of Germany (Address of principal executive office) Indicate by check mark whether the regis

AGREEMENT

EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G (including additional amendments thereto) relating to the Ordinary Shares of Immatics N.V. is being filed with the Securities and Exchange Commission on behalf of each of them. February 14, 2022 BAKER BROS. ADVISORS LP By

IMTX / Immatics NV / Nantahala Capital Management, LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Immatics N.V. (Name of Issuer) Ordinary shares, nominal value ?0.01 per share (Title of Class of Securities) N44445109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule

IMTX / Immatics NV / BAKER BROS. ADVISORS LP - SCHEDULE 13G Passive Investment

SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.

JOINT FILING STATEMENT

Exhibit 2 JOINT FILING STATEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common shares of Immatics N.

IMTX / Immatics NV / dievini Hopp BioTech holding GmbH & Co KG - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Under the Securities Exchange Act of 1934 (Amendment No. 1) IMMATICS N.V. (Name of Issuer) Ordinary shares, nominal value ?0.01 per share (Title of Class of Securities) N44445109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to des

POWER OF ATTORNEY

Exhibit 1 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS that each of the undersigned hereby constitutes and appoints Dr.

© Immatics. Not for further reproduction or distribution. Unlocking Immunotherapies for Solid Cancer Patients Immatics Corporate Presentation, December 2021

EX-99.2 3 dp163606ex9902.htm EXHIBIT 99.2 Exhibit 99.2 © Immatics. Not for further reproduction or distribution. Unlocking Immunotherapies for Solid Cancer Patients Immatics Corporate Presentation, December 2021 Forward - Looking Statements 2 This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained

Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401

Exhibit 99.1 PRESS RELEASE Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics? TCR Bispecific Program IMA401 ? Bristol Myers Squibb secures global exclusive license to Immatics? TCR bispecific program IMA401; companies will collaborate on development with Immatics retaining a co-promotion option in the US ? Immatics to receive upfront payment of $150 million and add